Abstract:Renal fibrosis is a characteristic of progressive renal diseases leading to end‐stage renal failure. Induction of renal fibrosis via the mouse unilateral ureteral occlusion (UUO) model occurs within 5 days making it a high throughput model to evaluate novel therapeutic targets. Transforming growth factor‐beta (TGF‐β) is a key signaling molecule in the pathogenesis of renal fibrosis mediated through its actions on its receptor, Activin A Receptor‐Like Kinase (ALK5). Previously, we have shown the anti‐TGF‐β antibody (1D11; clone 1D11.16.8) attenuates UUO‐induced renal fibrosis. Here, we evaluated and compared the dose‐dependent ability of an orally‐available ALK5 inhibitor (SB‐525334) to attenuate UUO‐induced tissue biomarkers. To minimize the number of necessary control groups and ensure all mice were handled similarly, all mice received intraperitoneal injections of PBS or 3 mg/kg 1D11 QD d‐1 through d4 and oral gavage administration of vehicle or SB‐525334 (10, 30 or 100 mg/kg) QD d‐1 through d5. On d0, mice (male, CD‐1, 8–9 weeks age) underwent sham (n=8) or permanent total ligation of the right ureter (UUO, n=12–13/group) via aseptic laparotomy. Five days post‐UUO or sham surgery, renal tissue from sham or obstructed kidney was collected for analysis of profibrotic mRNA biomarker expression, TGF‐β content, hydroxyproline content and renal fibrosis as expressed as collagen volume fraction (CVF; quantitated via histological image analysis of Picrosirius Red stained mid‐transverse kidney sections). Consistent with a pathophysiological response to ureteral obstruction, UUO reliably (100%) elicited hydronephrosis. UUO increased renal cortical mRNA expression of several fibrotic markers—fibronectin‐1 (FN‐1; 3.4±0.5 fold induction from sham), alpha‐smooth muscle actin (α‐SMA; 0.9±0.2 fold), collagen 1A1 (Col1A1; 12.7±4.2 fold) and collagen 3A1 (Col3A1; 5.8±0.8 fold) as well as increased renal cortical TGF‐β content (2.8±0.2 fold), hydroxyproline content (1.6±0.1 fold) and CVF (8.8±0.9 fold). 1D11 attenuated UUO‐induced increases in FN‐1 (45.5±5.6%), Col1A1 (61.3±9.6%) and Col3A1 (48.6±8.2%) mRNA expression, TGF‐β content (38.8±5.9% inhibition), hydroxyproline content (23.4±6.5%), and CVF (42.6±5.7%). High dose (100 mg/kg) SB‐525334 attenuated UUO‐induced increases in FN‐1 (77.8 ±6.4%), α‐SMA (111.0±23.6%), Col1A1 (77.1±4.1%) and Col3A1 (56.0±7.8%) mRNA expression, as well as TGF‐β content (35.2±6.3%), hydroxyproline content (46.5±4.4%), and CVF (73.7±4.8% inhibition). The current data demonstrate the importance of TGF‐β signaling in fibrotic consequences of ureteral obstruction. Additionally, UUO‐induced renal injury can be modulated by a parenterally administered biological agent (1D11) as well as by an orally administered small molecule (SB‐525334) thus eliminating the need for multiple dosing routes in future UUO studies where a reference agent is utilized.

Protective Role of Thrombin Activatable Fibrinolysis Inhibitor in Obstructive Nephropathy‐associated Tubulointerstitial Fibrosis

Mice Overexpressing Latent Tgf-Beta 1 Are Protected Against Renal Fibrosis In Obstructive Kidney Disease

Mice overexpressing latent TGF-β1 are protected against renal fibrosis in obstructive kidney disease

Expression of Connective Tissue Growth Factor in Renal Tubulointerstitial Fibrosis in Rats and Its Pathogenic Role

Tubulointerstitial Expression of Thrombosondin-1 in 5/6 Renal Ablation Rats

Thrombospondin-1 Short Hairpin RNA Suppresses Tubulointerstitial Fibrosis in the Kidney of Ureteral Obstruction by Ameliorating Peritubular Capillary Injury

Autophagy attenuates tubulointerstital fibrosis through regulating transforming growth factor-β and NLRP3 inflammasome signaling pathway

Effects of Transforming Growth Factor‐Beta (TGF‐β) Receptor I Inhibition on Renal Biomarkers and Fibrosis in Unilateral Ureteral Occluded (UUO) Mice.

Pivotal role of CD4+ T cells in renal fibrosis following ureteric obstruction

Pulmonary Hypertension is Ameliorated in Mice Deficient in Thrombin‐activatable Fibrinolysis Inhibitor

[Experimental Study on Effect of Matrine in Alleviating Renal Tubulointerstitial Fibrosis in Unilateral Ureteral Obstruction Model].

Dsba-L Mediated Renal Tubulointerstitial Fibrosis In Uuo Mice

Fluorofenidone Attenuates Tubulointerstitial Fibrosis by Inhibiting TGF-β1-Induced Fibroblast Activation

Expression of Connective Tissue Growth Factor in Renal Interstitial Fibrosis after Unilateral Ureteral Obstruction in Rats

Molecular mechanism of miR-382 in the pathogenesis of renal tubulointerstitial fibrosis

Loss of TIMP3 Enhances Interstitial Nephritis and Fibrosis.

Attenuation of renal injury by administration of TK-850, a dual inhibitor of TGF{beta}R1/MAP4K4

PAI-1 deficiency attenuates the fibrogenic response to ureteral obstruction

Effect of Tissue-derived Angiotensinogen on Kidney Injury and Fibrosis in Obstructive Nephropathy

The Protective Mechanism of Fluorofenidone in Renal Interstitial Inflammation and Fibrosis

MFAP4 deficiency alleviates renal fibrosis through inhibition of NF‐κB and TGF‐β/Smad signaling pathways